Andrea Fülöp

机构：Országos Korányi Tbc és Pulmonológiai Intézet

发表论文 25 篇 · 总被引 18331 次 · h-index 12

代表论文

• Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (2016 · New England Journal of Medicine · 被引 10309)
• Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer (2018 · New England Journal of Medicine · 被引 3711)
• Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater (2019 · Journal of Clinical Oncology · 被引 1740)
• Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021 · Journal of Clinical Oncology · 被引 1184)
• Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial (2020 · The Lancet Oncology · 被引 708)
• Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial (2017 · The Lancet Oncology · 被引 355)